Enliven Therapeutics, Inc. Common Stock (ELVN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 61
- Market Cap
- $3.9B
About Enliven Therapeutics, Inc. Common Stock
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
SentiSense also tracks daily options readings for Enliven Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Enliven Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.